4Sc Ag (FSCGF)

4SC AG was established in 1997. The Company is a biotechnology company. It discovers and develops targeted small molecule drugs for the treatment of cancer and autoimmune diseases in indications with a high unmet medical need and major economic potential. It operates in the two complementary segments of Discovery & Collaborative Business and Development. The Discovery & Collaborative Business segment, which is represented by 4SC Discovery GmbH, comprises all activities involved in early-stage drug research (drug discovery and lead optimisation) and its subsequent commercialisation. The scope of activities in the Development segment, collectively represented by 4SC AG, comprises the later stages of the pharmaceutical development process, i.e. preclinical and clinical development of 4SC drug candidates up to market approval. The Company's product pipeline comprises promising drug programmes at various stages of clinical development, as well as early-stage research projects. It is focussing on fields of research with an especially promising future - such as epigenetics, cancer stem cells, cancer immunotherapy and other, important cell communication patterns that contribute to the development and persistence of cancer and autoimmune diseases.